The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies
Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies
Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.
Herman will bring his experience as an investor in undervalued growth companies to this role as Advisory Director
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.
Dr. Andrea Small-Howard will be speaking as a part of the live Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. EDT, and she will be presenting the company during the 20-minute SPOTLIGHT SHOWCASE.
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This is the intersection of hard science, plant-based medicine, and solid business practices.
GB Sciences and their Spanish research partners at the Universidad de Sevilla (USE) have created terpene-containing nanoparticles. These first of their kind nanoparticles are central to GB Sciences' time-released pain formulations that are currently in animal trials at the NRC Canada, in preparation for an IND-filing for a US FDA-registered clinical trial.
If successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.
This is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio